Healthcare
Live Price
Offline$10.09
+1.51% today
1Y Change
-41.79%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telix Pharmaceuticals Limited (TLX) is a Healthcare stock with a market cap of $5.28B and listed on NASDAQ. The stock last traded around $10.09 and down 41.8% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +53.9%, EPS growth of -121.1%, a dividend yield of 0.0%. What stands out right now is revenue +53.9%, EPS -121.1%, free cash flow -388.4% with operating margin 2.1% and ROIC 1.8%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TLX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLX Max Drawdown
-62.12%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$7.6M
-95.3% YoY
FY Net Income
-$80.5M
+22.6% YoY
Free Cash Flow
-$60.7M
+14.6% YoY
Revenue Growth
+53.9%
EPS Growth
-121.1%
Gross Margin
50.8%
Net Margin
-0.9%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 783M | 503M | 160M | 8M |
| Gross Profit | 640M | 510M | 314M | 29M | -30M |
| Operating Income | 27M | 82M | 52M | -92M | -81M |
| EBITDA | 80M | 98M | 23M | -93M | -70M |
| Net Income | -11M | 50M | 5M | -104M | -81M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 213M | 710M | 123M | 116M | 22M |
| Total Assets | 1.8B | 1.5B | 398M | 261M | 110M |
| Total Liabilities | 1.1B | 948M | 249M | 175M | 106M |
| Shareholder Equity | 622M | 568M | 149M | 80M | 2M |
| Total Debt | 784M | 581M | 17M | 10M | 3M |
| Net Debt | 572M | -129M | -106M | -106M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
59M
+7.3% YoY
Capital Expenditures
1M
+81.0% YoY
Free Cash Flow
61M
+14.6% YoY
Key ratios
Gross Margin
50.8%
Operating Margin
2.1%
Net Margin
-0.9%
ROE
-2.1%
Debt / Equity
1.26x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.